FDA Approves Selinexor for R/R Diffuse Large B-Cell Lymphoma

On June 22, 2020, Karyopharm Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has approved oral Xpovio® (selinexor), the company’s first-in-class, selective inhibitor of nuclear export (SINE) compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. This indication was approved based on response rate under the FDA’s Accelerated Approval Program.

Read the corporate press release.

Posted 6/22/2020